| Literature DB >> 31337270 |
Jill M Pulley1, Jillian P Rhoads1, Rebecca N Jerome1, Anup P Challa1, Kevin B Erreger1, Meghan M Joly1, Robert R Lavieri1, Kelly E Perry1, Nicole M Zaleski1, Jana K Shirey-Rice1, David M Aronoff2,3.
Abstract
The promise of drug repurposing is to accelerate the translation of knowledge to treatment of human disease, bypassing common challenges associated with drug development to be more time- and cost-efficient. Repurposing has an increased chance of success due to the previous validation of drug safety and allows for the incorporation of omics. Hypothesis-generating omics processes inform drug repurposing decision-making methods on drug efficacy and toxicity. This review summarizes drug repurposing strategies and methodologies in the context of the following omics fields: genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, phenomics, pregomics, and personomics. While each omics field has specific strengths and limitations, incorporating omics into the drug repurposing landscape is integral to its success.Entities:
Keywords: big data; drug development; drug repurposing; omics; precision medicine
Year: 2019 PMID: 31337270 DOI: 10.1146/annurev-pharmtox-010919-023537
Source DB: PubMed Journal: Annu Rev Pharmacol Toxicol ISSN: 0362-1642 Impact factor: 13.820